Compare NIU & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NIU | SIGA |
|---|---|---|
| Founded | 2014 | 1995 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 200.8M | 223.8M |
| IPO Year | 2018 | 2016 |
| Metric | NIU | SIGA |
|---|---|---|
| Price | $2.03 | $3.44 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.50 | N/A |
| AVG Volume (30 Days) | 191.8K | ★ 628.6K |
| Earning Date | 05-18-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 13.24% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.13 |
| Revenue | N/A | N/A |
| Revenue This Year | $25.54 | N/A |
| Revenue Next Year | $17.70 | $224.81 |
| P/E Ratio | ★ N/A | $25.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.79 | $2.83 |
| 52 Week High | $5.67 | $9.29 |
| Indicator | NIU | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 43.42 | 62.69 |
| Support Level | $1.85 | $2.92 |
| Resistance Level | $2.04 | $4.84 |
| Average True Range (ATR) | 0.12 | 0.15 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 43.75 | 100.00 |
Niu Technologies designs, manufactures, and sells high-performance electric motorcycles, scooters, bicycles, and kick-scooters. The company has a product portfolio consisting of electric motorcycles, mopeds, and bicycle series, including the NQi, MQi, UQi, FQi series, and others, and micro-mobility series, including the kick-scooter series KQi and the e-bike series BQi. The company's principal operations and geographic markets are predominantly in the People's Republic of China. It also generates revenue from Europe and other regions.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.